Skip to main content

Advertisement

SpringerLink
Log in

Successful IL-17A inhibitor cycling in psoriatic arthritis patient: a case report and a literature review

  • Case Based Review
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Psoriatic arthritis is an inflammatory arthritis with heterogeneous disease presentation. The most affected clinical domain of the disease determines the therapeutic approach. We report the case of a 34-year-old man with all six crucial domains of psoriatic arthritis (psoriasis, peripheral arthritis, axial skeletal manifestations, dactylitis, nail changes, and enthesitis) treated unsuccessfully with conventional synthetic DMARDs, NSAID’s, and steroids as well as topical treatment and phototherapy. With golimumab as the first line of bDMARD partial remission was achieved. After 24 months the treatment was switched to secukinumab due to secondary inefficacy. The psoriasis and psoriatic arthritis relapsed after 21 months of treatment with secukinumab. The patient was cycled to ixekizumab with an excellent result. IL-17A inhibitor cycling may be a successful treatment option in some difficult to treat psoriatic arthritis patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(suppl 2):ii14-17

    PubMed  PubMed Central  Google Scholar 

  2. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673

    Article  Google Scholar 

  3. Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW et al (2016) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68(5):1060–1071

    PubMed  Google Scholar 

  4. Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M et al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79(6):700–712

    Article  Google Scholar 

  5. Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S et al (2020) Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 FUTURE 1 study. ACR Open Rheumatol 2(1):18–25

    Article  Google Scholar 

  6. Georgakopoulos JR, Phung M, Ighani A, Lam K, Yeung J (2019) Biologic switching between interleukin 17A antagonists secukinumab and ixekizumab: a 12-week, multicenter, retrospective study. J Eur Acad Dermatol Venereol 33(1):e7-8

    Article  CAS  Google Scholar 

  7. Bokor-Billmann T, Schäkel K (2019) No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis. J Dermatol Treat 30(3):216–220

    Article  CAS  Google Scholar 

  8. Amschler K, Phillip S, Mohr J, Wilsmann-Theis D, Poortinga S, Gerdes S et al (2020) Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab. Dermatol Online J 26(1):13030. https://doi.org/10.5070/D3261047182

    Article  PubMed  Google Scholar 

  9. van Vollenhoven RF (2007) Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis 66(7):849–851

    Article  Google Scholar 

  10. Redlich K, Schett G, Steiner G, Hayer S, Wagner EF, Smolen JS (2003) Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum 48(12):3308–3319

    Article  CAS  Google Scholar 

  11. Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E et al (2017) Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Semin Arthritis Rheum 47(2):183–192

    Article  CAS  Google Scholar 

  12. Genovese MC, Combe B, Kremer JM, Tsai T-F, Behrens F, Adams DH et al (2018) Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2. Rheumatology 57(11):2001–2011

    Article  CAS  Google Scholar 

  13. Egeberg A, Bryld LE, Skov L (2019) Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. J Am Acad Dermatol 81(1):173–178

    Article  CAS  Google Scholar 

  14. Caldarola G, Mariani M, Pirro F, Nicolotti N, Burlando M, Calabrese L et al (2021) Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice. Expert Opin Biol Ther 21(2):279–286. https://doi.org/10.1080/14712598.2021.1849133

    Article  CAS  PubMed  Google Scholar 

  15. Bruin G, Loesche C, Nyirady J, Sander O (2017) Population pharmacokinetic modeling of secukinumab in patients with moderate to severe psoriasis. J Clin Pharmacol 57(7):876–885

    Article  CAS  Google Scholar 

  16. Liu L, Lu J, Allan BW, Tang Y, Tetreault J, Chow C et al (2016) Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res 9:39–50

    Article  CAS  Google Scholar 

  17. Warren RB, Brnabic A, Saure D, Langley RG, See K, Wu JJ et al (2018) Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab. Br J Dermatol 178(5):1064–1071

    Article  CAS  Google Scholar 

  18. Spindeldreher S, Maillère B, Correia E, Tenon M, Karle A, Jarvis P et al (2018) Secukinumab demonstrates significantly lower immunogenicity potential compared to ixekizumab. Dermatol Ther 8(1):57–68

    Article  Google Scholar 

  19. Combe B, Rahman P, Kameda H, Cañete JD, Gallo G, Agada N et al (2020) Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. Arthritis Res Ther 22(1):14

    Article  CAS  Google Scholar 

  20. Conti A, Peccerillo F, Amerio P, Balato A, Bardazzi F, Bianchi L et al (2019) Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. Br J Dermatol 180(6):1547–1548

    Article  CAS  Google Scholar 

  21. Sherman S, Solomon Cohen E, Amitay-Laish I, Hodak E, Pavlovsky L (2019) IL-17A inhibitor switching - efficacy of ixekizumab following secukinumab failure. A single-center experience. Acta Derm Venereol 99(9):769–773

    Article  CAS  Google Scholar 

  22. Gasslitter I, Kirsten N, Augustin M, Torz K, Mrowietz U, Eyerich K et al (2019) Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. Arch Dermatol Res 311(5):421–424

    Article  Google Scholar 

  23. Lockshin B, Cronin A, Harrison RW, McLean RR, Anatale-Tardiff L, Burge R et al (2021) Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: the Corrona Psoriasis Registry. Dermatol Ther 34(2):e14808

    Article  CAS  Google Scholar 

  24. Herrera-Acosta E, Garriga-Martina GG, Suárez-Pérez JA, Martínez-García EA, Herrera-Ceballos E (2020) Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: Real-world practice. Dermatol Ther 33(3):e13313

    Article  CAS  Google Scholar 

  25. Migliore A, Pompilio G, Integlia D, Zhuo J, Alemao E (2021) Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis. Ther Adv Musculoskelet Dis. https://doi.org/10.1177/1759720X211002682

    Article  PubMed  PubMed Central  Google Scholar 

  26. Prado MS, Bendtzen K, Andrade LEC (2017) Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events. Expert Opin Drug Metab Toxicol 13(9):985–995

    Article  CAS  Google Scholar 

Download references

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Author information

Authors and Affiliations

  1. Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, School of Medicine, University Hospital Center Zagreb, University of Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia

    Marko Barešić, Ljiljana Smiljanić Tomičević, Branimir Anić & Miroslav Mayer

Authors
  1. Marko Barešić
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ljiljana Smiljanić Tomičević
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Branimir Anić
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miroslav Mayer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ljiljana Smiljanić Tomičević.

Ethics declarations

Conflict of interest

The authors declare that this manuscript is original, has not been published before, and is not currently being considered for publication elsewhere. We have no conflicts of interest associated with this publication, and there has been no financial support for this work that could have influenced its outcome. The corresponding author confirms that the manuscript has been read and approved for submission by all named authors with subsequent modifications. All the authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Informed consent

Informed consent was obtained from the patient included in this case report.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barešić, M., Smiljanić Tomičević, L., Anić, B. et al. Successful IL-17A inhibitor cycling in psoriatic arthritis patient: a case report and a literature review. Rheumatol Int 42, 365–370 (2022). https://doi.org/10.1007/s00296-021-05065-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-021-05065-1

Keywords

Search

Navigation